ARVN Quote, Financials, Valuation and Earnings

Moderna has a net margin of -48.05% compared to Arvinas's net margin of 0.7%. Arvinas's return on equity of -52.97% beat Moderna's return on equity of -17.44%.

Arvinas has a consensus price target of $63.42, signalling upside risk potential of 268.3%. On the other hand Moderna has an analysts' consensus of $69.87 which suggests that it could grow by 102.75%. Given that Arvinas has higher upside potential than Moderna, analysts believe Arvinas is more attractive than Moderna.

Arvinas has a beta of 1.875, which suggesting that the stock is 87.523% more volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Arvinas quarterly revenues are $102.4M, which are smaller than Moderna quarterly revenues of $1.9B. Arvinas's net income of -$49.2M is lower than Moderna's net income of $13M. Notably, Arvinas's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 7.40x versus 2.64x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -48.05% compared to Arvinas's net margin of 25.23%. Arvinas's return on equity of -52.97% beat Pfizer's return on equity of 4.63%.

Arvinas has a consensus price target of $63.42, signalling upside risk potential of 268.3%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 20.32%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

Arvinas has a beta of 1.875, which suggesting that the stock is 87.523% more volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.36% to investors and pays a quarterly dividend of $0.42 per share. Arvinas pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Arvinas quarterly revenues are $102.4M, which are smaller than Pfizer quarterly revenues of $17.7B. Arvinas's net income of -$49.2M is lower than Pfizer's net income of $4.5B. Notably, Arvinas's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 7.40x versus 2.53x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Arcus Biosciences has a net margin of -48.05% compared to Arvinas's net margin of -191.67%. Arvinas's return on equity of -52.97% beat Arcus Biosciences's return on equity of -46.73%.

Arvinas has a consensus price target of $63.42, signalling upside risk potential of 268.3%. On the other hand Arcus Biosciences has an analysts' consensus of $33.20 which suggests that it could grow by 140.23%. Given that Arvinas has higher upside potential than Arcus Biosciences, analysts believe Arvinas is more attractive than Arcus Biosciences.

Arvinas has a beta of 1.875, which suggesting that the stock is 87.523% more volatile than S&P 500. In comparison Arcus Biosciences has a beta of 0.867, suggesting its less volatile than the S&P 500 by 13.347%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcus Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Arcus Biosciences pays out -- of its earnings as a dividend.

Arvinas quarterly revenues are $102.4M, which are larger than Arcus Biosciences quarterly revenues of $48M. Arvinas's net income of -$49.2M is higher than Arcus Biosciences's net income of -$92M. Notably, Arvinas's price-to-earnings ratio is -- while Arcus Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 7.40x versus 4.52x for Arcus Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -48.05% compared to Arvinas's net margin of 36.03%. Arvinas's return on equity of -52.97% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Arvinas has a consensus price target of $63.42, signalling upside risk potential of 268.3%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,029.20 which suggests that it could grow by 48.97%. Given that Arvinas has higher upside potential than Regeneron Pharmaceuticals, analysts believe Arvinas is more attractive than Regeneron Pharmaceuticals.

Arvinas has a beta of 1.875, which suggesting that the stock is 87.523% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Arvinas quarterly revenues are $102.4M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Arvinas's net income of -$49.2M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Arvinas's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 7.40x versus 5.74x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.